Macimorelin
Growth Hormone Secretagogue Receptor Agonist — VARIOUS
Also known as: ARD 07, D-87575, EP1572, macimorelin acetate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Macimorelin is an ofm drug in the Growth Hormone Secretagogue Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Growth Hormone Secretagogue Receptor Agonists. DrugCentral lists 1 molecular target, including GHSR.
- Approval status: ofm (first approved 2017 by the FDA).
- Drug class: Growth Hormone Secretagogue Receptor Agonist.
- Mechanism of action: Growth Hormone Secretagogue Receptor Agonists.
- Molecular targets: GHSR (1 listed in DrugCentral).
- ATC code: V04CD06 (Tests for pituitary function).
- Molecular formula: C26H30N6O3; molecular weight 474.56 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Diagnosis (1)
- Adult growth hormone deficiency
Mechanism & targets
| Mechanism of action (MoA) | Growth Hormone Secretagogue Receptor Agonists |
|---|---|
| Established pharmacologic class | Growth Hormone Secretagogue Receptor Agonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Growth hormone secretagogue receptor type 1 | GHSR | agonist | IC50 7.81 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-01-11 | EMA | — | AETERNA ZENTARIS GMBH | |
| 2017-12-20 | FDA | — | AETERNA ZENTARIS GMBH | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V04CD06 | VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for pituitary function |
Chemical structure
| Molecular formula | C26H30N6O3 |
|---|---|
| Molecular weight | 474.56 g/mol |
| CAS number | — |
| InChIKey | VPBQKRKRYYPMOF-DHIUTWEWSA-N |
| PubChem CID | 9804938 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Macimorelin work?
Macimorelin is classified as Growth Hormone Secretagogue Receptor Agonists; its molecular targets in DrugCentral include GHSR (agonist).
When was Macimorelin first approved?
Macimorelin was first approved by the FDA in 2017.
What drug class does Macimorelin belong to?
Macimorelin is in the Growth Hormone Secretagogue Receptor Agonist class.
What is the chemical formula of Macimorelin?
Macimorelin has the molecular formula C26H30N6O3 and a molecular weight of 474.56 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5271 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2364617 — compound record and bioactivity
- PubChem CID 9804938 — chemical identifiers
- DrugBank DB13074 — drug record
- FDA UNII 8680B21W73 — substance identity
- DailyMed: FDA labels for Macimorelin — current prescribing information (label search)
- UniProt Q92847 (GHSR) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.